Pfizer recalls 3 types of blood pressure medication due to possible cancer risk


NEW YORK (WFXR) – Pfizer has issued a nationwide recall of certain blood pressure medications due to the presence of nitrosamine above the acceptable daily intake (ADI) level.

The recall, announced this week, affects Accuretic tablets and two generics distributed by Greenstone: quinapril and hydrochlorothiazide, and quinapril HCI/hydrochlorothiazide.

Pfizer will draw six batches of Accuretic tablets, one batch of quinapril and hydrochlorothiazide tablets and four batches of quinapril HCI/hydrochlorothiazide tablets.

Health officials say you can also find nitrosamines in water and foods, including dairy products, vegetables, and salted and grilled meats. However, exposure to nitrosamines above the ADI levels, for long periods, may increase the risk of cancer.

The recalled products are used to help treat hypertension and lower blood pressure to reduce the risk of fatal and non-fatal cardiovascular events, strokes and myocardial infarction. Pfizer recommends that patients taking this drug talk to their doctor about alternative treatment options.

The recalled drugs include Accuretic™ (quinapril hydrochloride/hydrochlorothiazide) tablets (top row), as well as quinapril and hydrochlorothiazide tablets (first photo, second row) and quinapril hydrochloride/hydrochlorothiazide tablets (bottom two photos, second row). (Pfizer)

The recalled products were distributed from November 2019 to March 2022 in the United States and Puerto Rico. Below are the products on the recall list.

  • Accuretic™ (quinapril hydrochloride/hydrochlorothiazide) tablets, 10/12.5mg
  • Accuretic™ (quinapril hydrochloride/hydrochlorothiazide) tablets, 20/12.5mg
  • Accuretic™ (quinapril hydrochloride/hydrochlorothiazide) tablets, 20/25mg
CDN Batch number Expiration date Strength Configuration/Counting
0071-3112-23 FG5379 08/2024 10/12.5mg 1 bottle of 90 units
0071-0222-23 EA6686 04/2022 10/12.5mg 1 bottle of 90 units
0071-5212-23 FG5381 08/2024 20/12.5mg 1 bottle of 90 units
0071-0220-23 EA6665 04/2022 20/12.5mg 1 bottle of 90 units
0071-0220-23 CN0640 04/2022 20/12.5mg 1 bottle of 90 units
0071-0223-23 ET6974 02/2023 20/25mg 1 bottle of 90 units
Data from Pfizer
  • quinapril and hydrochlorothiazide tablets, 20/25mg
  • quinapril hydrochloride/hydrochlorothiazide tablets, 20/12.5mg
  • quinapril hydrochloride/hydrochlorothiazide tablets, 20/25mg
CDN Batch number Expiration date Strength Configuration/Counting
59762-5225-9 FE3714 02/2023 20/25mg 1 bottle of 90 units
59762-0220-1 DN6931 03/2023 20/12.5mg 1 bottle of 90 units
59762-0220-1 ED3904 03/2023 20/12.5mg 1 bottle of 90 units
59762-0220-1 ED3905 03/2023 20/12.5mg 1 bottle of 90 units
59762-0223-1 DP3414 02/2023 20/25mg 1 bottle of 90 units
Data from Pfizer

Pfizer said wholesalers and distributors of any of these products should stop use and distribution and immediately quarantine the product.

More information about this recall can be found on the Pfizer website.


whnt

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button